What causes PLS? Did I cause this?

This is the question almost every newly diagnosed PLS patient asks themselves in the first weeks. What did I do? Was it the smoking? The job? The stress? Something I ate? Something I missed? The mind reaches for a story, a wrong choice, a moment that could have gone differently. This page is an honest attempt to answer it. The short version is that the cause of adult sporadic Primary Lateral Sclerosis is unknown, and almost certainly nothing you did is the reason this happened to you. The long version, with the actual evidence, is below.

Why this page exists

A diagnosis like PLS is the kind of news that breaks open every assumption about your life, and one of the first instincts is to look back through the rearview mirror for a cause. Did drinking too much coffee do this? Did the job? Did the cigarettes thirty years ago? Did the cannabis? Did the sport injury? Did the soccer? The grief? The chemicals at work? The water? The genes from a grandfather you never met? Patients and families spend hours, sometimes months, going through their own histories looking for the moment that explains it.

This page exists because there is a real answer to that search, and it is not the answer most people expect. The answer is that the medical and epidemiological literature on adult sporadic PLS — the form that affects almost everyone with this diagnosis — has identified essentially no environmental risk factors. There is no exposure, no behavior, no occupation, no substance, no event that has been shown to cause it. The cause is unknown. And the absence of a cause is, paradoxically, one of the most important things a newly diagnosed patient can hear, because it forecloses the worst of the self-blame.

The honest baseline: the cause of adult sporadic PLS is unknown

Primary Lateral Sclerosis is a rare disease — roughly 1 to 4 percent of all motor neuron disease cases, which are themselves rare. Because it is so uncommon, the epidemiological studies that would be needed to identify environmental risk factors are difficult to do. You need very large populations, careful exposure histories, decades of follow-up, and statistical power that small disease cohorts cannot provide. As a result, almost everything we know about MND risk factors comes from research on ALS, the more common form of motor neuron disease.

Here is what major reference sources say about PLS specifically:

• The Mayo Clinic states: "The cause of PLS that begins in adulthood is not known. In most people, the disease is not inherited."
• The Cleveland Clinic states: "The cause of sporadic PLS is unknown."
• The NORD (National Organization for Rare Disorders) entry on PLS states there are "no recognized environmental risk factors" for adult-onset PLS.
• Medscape's clinical reference on PLS lists no specific genes associated with adult PLS and no recognized environmental risk factors.

This is not a polite hedge. It is a substantive statement: when the entire clinical literature on a disease has been searched for environmental causes and nothing has been found, that absence is itself meaningful. It tells you that whatever causes adult PLS is almost certainly not something common — not a widespread exposure, not a popular behavior, not a known occupational hazard. If it were, the epidemiology would have detected it by now.

What is actually established

For sporadic adult PLS, the only things consistently associated with the disease across studies are the same ones associated with ALS: increasing age and male sex. Most patients are diagnosed in their fifties or sixties. Men are affected slightly more often than women, with a ratio of roughly 1.5:1 in some cohorts. Neither of these is a "cause" in any meaningful sense — they are demographic patterns, not things you did or didn't do.

Juvenile PLS is a distinct exception. It is caused by mutations in the ALS2 gene (which encodes a protein called alsin) and follows an autosomal recessive inheritance pattern. This form affects children and teenagers, runs in specific families, and has a known genetic mechanism. It accounts for a tiny minority of PLS cases. If you are an adult who developed PLS in midlife or later, with no family history, you almost certainly do not have the ALS2 form, and a genetic cause is highly unlikely.

Cannabis and smoking

Patients who used cannabis for years before their diagnosis sometimes wonder whether their use was the cause. The literature does not support this concern. Across the entire body of motor neuron disease research, cannabis is studied as a potential treatment, not as a cause.

Specifically:

• Multiple preclinical studies in the SOD1 G93A mouse model — the standard preclinical model for ALS — have shown that cannabinoids have antioxidant, anti-inflammatory, and neuroprotective effects. In these models, cannabis extracts have delayed disease onset and slowed progression, not accelerated it.
• The CANALS Phase 2 trial (Riva et al., Lancet Neurology 2019) tested nabiximols (a 1:1 THC:CBD pharmaceutical cannabinoid) in 60 motor neuron disease patients, including PLS patients. The drug was well tolerated. There was no signal that it accelerated disease or worsened motor neuron function — quite the opposite, it produced a small but statistically significant improvement in spasticity.
• No epidemiological study has identified cannabis use as a risk factor for ALS or PLS. Surveys of ALS patient populations (such as the Cedars-Sinai cannabis survey) have asked patients how they use cannabis for symptom management, not whether using cannabis caused their disease — because there is no reason to suspect it does.

There is a separate, important point about why cannabis is unlikely to cause motor neuron degeneration on biological grounds. The pathology of PLS involves degeneration of upper motor neurons — particularly the large pyramidal Betz cells in layer V of the motor cortex — and progressive loss of the corticospinal tract. The molecular mechanisms implicated in this degeneration are TDP-43 mislocalization, glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, and stress-granule abnormalities. THC binds to CB1 cannabinoid receptors, which are densely expressed on presynaptic terminals in the cerebellum, basal ganglia, and motor cortex. Activating CB1 reduces presynaptic neurotransmitter release — including glutamate release. If anything, this should reduce glutamate excitotoxicity, not cause it. The biological case for cannabis as a cause of motor neuron degeneration is weak and theoretical, while the biological case against it is grounded in basic pharmacology.

What about the online forum reports and occasional case studies of PLS or ALS patients who were heavy cannabis users? These exist, and they are noticed, but they need to be read in the context of base rates. Cannabis use is extremely common. In countries where it has been studied, the lifetime prevalence of cannabis use in adults is between 20 and 50 percent. Motor neuron disease is rare. Among any group of MND patients, some will have used cannabis at some point, just as some will have drunk coffee, eaten gluten, or watched television — not because those things cause MND, but because they are common in the general population. A correlation between two common-and-rare populations is not evidence of causation. Without a controlled epidemiological study showing that cannabis users have a higher rate of MND than non-users, the forum reports and case anecdotes do not support the hypothesis.

Tobacco smoking is similar. Some early studies suggested a possible weak association between smoking and ALS (not PLS specifically), but the evidence has been mixed and the effect sizes, when present, have been small. A few meta-analyses have found a modest association in women but not men. Neither of these patterns has been shown to apply to PLS, and even in ALS the magnitude of the effect is too small to identify smoking as a meaningful cause in any individual case.

The general health risks of long-term heavy cannabis or tobacco use are real — bronchitis, reduced lung function, cognitive effects, dependence, cardiovascular effects. These are well established. They are also completely separate from causing motor neuron disease. They affect different organ systems through different mechanisms. The fact that decades of smoking might have caused mild lung problems or bronchitis tells you nothing about whether it caused upper motor neuron degeneration in the brain.

Exercise and sedentary work

This is one of the most counter-intuitive findings in MND epidemiology, and it is worth knowing about because it directly contradicts the intuition that "I sat at a desk too much and my muscles weakened from disuse."

The data on physical activity and ALS risk consistently points in the opposite direction from what most people expect. Multiple studies, using different methodologies, have found that more vigorous physical activity is associated with higher ALS risk, not lower. The strongest evidence comes from Mendelian randomization studies — a method that uses genetic variants to control for confounding factors and infer causation rather than mere correlation. The 2021 eBioMedicine Mendelian randomization study by Julian and colleagues found that genetically predicted higher physical activity levels were associated with elevated ALS risk. The 2023 Brain systematic review by Visser and colleagues found similar evidence across multiple study types. The 2024 Neurology paper on physical activity, fitness, and ALS risk reinforced the same direction. Specifically, an additional 10 kJ/kg of daily physical activity (equivalent to roughly 45 minutes of brisk walking) was associated with an odds ratio of approximately 1.47 for developing ALS — a 47 percent increase in risk per unit of additional daily activity.

Why? The proposed mechanism is that motor neurons are among the most metabolically demanding cells in the human body. Sustained high-intensity firing during vigorous exercise increases their oxidative load, glutamate release, and energetic stress. In genetically susceptible individuals, this may accelerate the cellular damage pathways that lead to motor neuron degeneration. This is the same biology that makes professional athletes (especially in contact sports like American football, soccer, and rugby) and military personnel epidemiologically over-represented among ALS patients. The Italian footballer ALS cluster is one of the strongest pieces of evidence in this area, and the elevated ALS rate among US veterans (twice the general population, well-documented) is another.

The implication for sedentary workers is clear and surprising: if anything, a lifetime of office work is likely to have been protective against developing ALS, not a cause of it. The risk runs in the direction of high physical exertion, not low. There is no published evidence that sedentary occupation, prolonged sitting, or lack of exercise causes or contributes to motor neuron disease. Patients who spent decades at a desk should not blame their career choice for their PLS.

This finding does not mean that exercise is bad for everyone or that sitting is good — far from it. The general health benefits of moderate physical activity (cardiovascular health, metabolic health, mental health, longevity) are overwhelming. What this finding does mean is that the very specific pathway from "sitting too much" to "developing motor neuron disease" does not exist in the data. If you sat at a desk for forty years, that is not why you have PLS.

Nerve compression and leg crossing

Patients sometimes wonder whether decades of sitting cross-legged might have caused nerve damage that progressed into PLS. There is a clinically important distinction here that is worth understanding because it can clarify what is happening — and what is not.

Habitual leg crossing can cause a real, well-documented nerve injury. The condition is called peroneal nerve palsy (or fibular nerve palsy). The common peroneal nerve passes around the head of the fibula on the outside of the knee, where it sits very close to the surface and is exposed. Sustained pressure on this area — from crossing legs for long periods, from prolonged squatting, from leg casts, or from lying with the leg compressed — can compress the nerve and cause it to malfunction. The classic presentation is foot drop: the inability to lift the front of the foot off the ground when walking. Major medical references including Cleveland Clinic, StatPearls, the Merck Manual, and Mount Sinai all list "habitual leg crossing" as a recognized cause of peroneal palsy.

Here is why this is not the same as PLS, even though the surface symptoms can look similar:

The biology is one-directional: motor cortex → spinal cord → peripheral nerve → muscle. Damaging the peroneal nerve at the knee — at the bottom of that chain — does not propagate upward to cause Betz cells in the motor cortex to die. A focal compression injury cannot cause a central upper motor neuron disease. The two conditions affect completely different parts of the nervous system through different mechanisms.

However, there is a useful nuance worth raising with a neurologist. If a patient with PLS also has years of habitual leg crossing, it is theoretically possible that the leg weakness they experience is partly central (from PLS) and partly peripheral (from peroneal nerve compression). The two would compound each other. Importantly, the peripheral component is potentially reversible: stopping the leg-crossing behavior, allowing the peripheral nerve to recover, and potentially confirming the diagnosis with EMG and nerve conduction studies could improve the leg function even though the underlying PLS continues. This is worth asking a neurologist about as a specific clinical question:

A neurologist familiar with motor neuron disease will know exactly how to address this. If there is a peripheral compression component, it can be confirmed with electrodiagnostic testing, and addressing it might improve walking even though it cannot stop the underlying disease.

Note that the diagnostic literature explicitly recommends that motor neuron disease be considered in the differential when a patient presents with foot drop, and conversely that peripheral nerve compression be considered when patients present with what looks like motor neuron disease. The fact that your doctors landed on a PLS diagnosis means they did this work — they distinguished the central from the peripheral by examination, EMG, and imaging. The leg crossing did not fool them into a wrong diagnosis. Their conclusion that you have PLS reflects the bilateral, progressive, hyperreflexic, spastic, central pattern of damage that defines the disease — none of which can be produced by a focal peripheral compression.

Other things people wonder about

The list of things patients have wondered about — and that researchers have looked into and failed to confirm — is long. For completeness:

• Heavy metal exposure (lead, mercury, manganese, aluminum) has been studied repeatedly. Some studies have suggested weak associations with ALS in occupational cohorts, but the evidence is inconsistent and has not been confirmed in larger studies. No association with PLS specifically.
• Pesticides and agricultural chemicals — same story. Some weak signals in farming populations for ALS, no consistent finding for PLS.
• Electromagnetic field exposure from electrical work or living near power lines — studied, mixed results, no convincing evidence.
• Head trauma and concussion — moderate evidence of association with ALS in athletes (the Italian footballer cluster again, plus American football), but unclear whether this reflects head trauma specifically or the high-exertion physical activity that accompanies it. No data on PLS.
• Diet — extensively studied. No specific food, supplement, or dietary pattern has been convincingly linked to causing or preventing motor neuron disease.
• Stress and grief — extensively wondered about by patients, never established as a cause in any rigorous study.
• Viral or bacterial infection — studied, no consistent evidence.
• Vaccinations — studied, no association.

The pattern across the entire risk-factor literature for sporadic adult motor neuron disease is the same: weak signals, inconsistent findings, no smoking gun. This is itself the answer. If there were a clear, dominant, common cause, decades of epidemiological research would have found it. They have not, because there isn't one.

You did not cause this

The hard reframe is this: looking back through your life for the moment that caused your PLS is, with overwhelming probability, looking for something that does not exist. The disease is not a punishment for a wrong choice. It is not the result of a habit, a job, a substance, or a lifestyle. The cellular damage that underlies it appears to begin years or decades before symptoms emerge, and the triggers — whatever they are — do not appear to be things that any individual person could have avoided through better choices.

Self-blame is one of the heaviest weights newly diagnosed patients carry. Family members sometimes carry it too — wondering whether they should have insisted on different habits, different doctors, different choices for their loved one. The evidence does not support any of this. There is nothing you would have known to do differently, because there is nothing that has been shown to make a difference.

This is hard to sit with because the human mind wants a story, an arc, a cause and an effect. "It just happens" is not a satisfying explanation. But it is, in this case, the accurate one. Adult sporadic PLS happens to people who did everything right and to people who did some things wrong. It happens to athletes and to office workers, to lifelong non-smokers and to lifelong smokers, to people with perfect diets and to people with terrible ones. The common thread among PLS patients is not a behavior. It is bad luck, in the most literal biological sense.

What you can do now

If looking backward for a cause is mostly fruitless, looking forward for what to do is not. There is a real distinction between what caused this (unknown, almost certainly not your fault) and what to do about it (knowable, actionable, worth your energy).

Things that are worth doing:

• Read the prognosis page. The natural history data on PLS is meaningfully better than what most people assume when they first hear "motor neuron disease." Most people with PLS live for decades after diagnosis. This matters, and it matters early.
• Read the spasticity management page. Spasticity is the dominant symptom in PLS, and there are real treatments that can change daily quality of life. This is the single highest-leverage area to focus on.
• Read the targeting compensatory circuits page. There are specific compounds — dalfampridine, ropinirole, ultra-high-dose methylcobalamin — that have evidence in MND and are worth discussing with a neurologist familiar with the literature.
• Find a multidisciplinary care team. The single biggest modifiable factor in PLS outcomes is having a coordinated team of specialists who know the disease.
• Connect with the PLS community. PLS is rare, and finding others who actually understand the disease — its slow timeline, its specific symptoms, its decisions — is one of the most valuable things a patient can do.

Things that are worth letting go of:

• The search for a personal cause. It is almost certainly not productive, and continuing it usually adds psychological weight without yielding answers.
• Self-blame about cannabis use, smoking history, sedentary work, exercise habits, diet choices, or any of the other behaviors patients commonly second-guess. None of these has been established as a cause.
• Guilt directed at family members or caregivers about choices they did or did not make. They did not cause this either.

The goal of this page is not to dismiss the question. The question is real and the impulse to ask it is human. The goal is to give the most honest, complete answer the literature supports, so that patients and families can stop carrying a weight that the science does not require them to carry.

This page is not medical advice. If you have a specific question about your own clinical picture — including whether peripheral nerve compression might be contributing to your symptoms — discuss it with a neurologist familiar with motor neuron disease.